OXB Revenue
Pharmaceutical Manufacturing
Oxford, England, United Kingdom
501-1000 Employees (View 698 on Prospeo)
OXB revenue & valuation
| Annual revenue | $71,300,000 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $228,000,000 |
| Total funding | $128,100,000 |
Company overview
| Headquarters | Windrush Court, Transport Way, Oxford, Oxfordshire OX4 6LT, GB |
| Phone number | +441865783000 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Process Development, GMP, Manufacturing, Immunotherapy, AAV, Gene Therapy, Cell Therapy, Cdmo, Advanced Therapies, Viral Vector Gmp Manufacturing, Cell And Gene Therapy, Lentiviral Vectors |
| Employees | 501-1000 |
| Socials |
OXB Email Formats
OXB uses 5 email formats. The most common is {first name}.{last name} (e.g., john.doe@oxfordbiomedica.co.uk), used 57.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@oxfordbiomedica.co.uk | 57.5% |
{first initial}.{last name} | j.doe@oxfordbiomedica.co.uk | 23% |
{first name}.{last name} | john.doe@oxb.com | 12% |
{first initial}.{last name} | j.doe@oxb.com | 4% |
{first initial} | j@oxfordbiomedica.co.uk | 1% |
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
Employees by Management Level
Total employees: 501-1000
Employees by Department
OXB has 398 employees across 15 departments.
Departments
Number of employees
Funding Data
Explore OXB's funding history, including investment rounds, total capital raised, and key backers.
OXB Tech Stack
Discover the technologies and tools that power OXB's digital infrastructure, from frameworks to analytics platforms.
Video players
Security
Security
Form builders
Analytics
Cookie compliance
Miscellaneous
JavaScript libraries
JavaScript libraries
JavaScript libraries
JavaScript libraries
CDN
India
Canada
Germany
United States
Netherlands
France
Frequently asked questions
Key Contact at OXB
4.8
40,000 users
